Summary from the extraordinary general meeting of Immunovia
Extraordinary General Meeting of Immunovia AB (publ), 556730-4299, has been held in the confernce room ”Gamla Gästmatsalen”, House 302, Medicon Village, Scheelevägen 2, 223 63 Lund, December 9, 2016. Below is a summary of the resolutions of the extraordinary general meeting.
Election of Board of Directors
It was noted that the board member Patrik Dahlén and the deputy director Christer Wingren have chosen to leave their assignments in the board. Christer Wingren will remain in his position as Chief Technology Officer in the management of Immunovia and as a professor in Immune Technology at Lund University.
To fill the vacancy, and to bring new experience to the Board, Ann-Christine Sundell and Hans Johansson were elected as new directors.
Fees to the newly elected board members
It was resolved that Ann-Christin Sundell, until the next AGM, will receive a compensation of SEK 60,000 (she served as co-opted member of the Board since August 2016). The meeting also resolved to grant Hans Johansson a compensation of SEK 40,000 until the next AGM.
The decisions were unanimous.
Immunovia AB (publ)
The Board of directors
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.